Decentralized clinical trials (DCTs) use remote visits, home health, local labs/pharmacies, and digital tools to reduce reliance on centralized trial sites. 2026 commentaries and case studies show that DCTs can improve access, enrollment speed, and representativeness, but the benefits are uneven across populations [1][2][3].

Populations Most Likely to Benefit

1. Patients Far from Major Academic or Urban Centers

Why

• Traditional site‑based trials cluster around urban academic hospitals. Patients living in rural or semi‑rural areas face high travel time and cost barriers.

DCT impact

• Local labs, local imaging centers, and home visits remove the need for frequent long‑distance travel.

• Evidence from “direct‑to‑patient” and hybrid models indicates improved enrollment and retention when patients can participate from home or nearby community providers [1][2].

2. Patients with Mobility, Disability, or Caregiving Constraints

Examples

• Elderly patients with frailty or falls risk.

• People with disabilities that limit travel.

• Primary caregivers for children, elders, or disabled relatives.

Benefits

• Televisits, home nursing, and couriered study drugs make participation feasible for those who could not reliably attend on‑site visits.

• Reduced need to arrange time off work or alternative caregiving.

3. Working‑Age Adults with Limited Leave and Hourly Workers

Problem

• Many working‑age adults, particularly hourly and gig workers, lack paid leave or flexible schedules. Frequent site visits translate to lost wages and job instability.

DCT advantages

• Evening/weekend telehealth visits.

• Asynchronous data capture (via apps, wearables, ePROs).

• Use of local pharmacies for drug dispensing.

This tends to disproportionately benefit lower‑income participants who otherwise would be under‑represented.

4. Under‑represented Racial/Ethnic and Socioeconomic Groups

Why

• Structural barriers (location of trial sites, transportation costs, mistrust, caregiving burdens) keep many under‑represented groups out of traditional trials.

Evidence signals

• Analyses of DCT and “direct‑to‑patient” models show improved patient access and representation, including more diverse cohorts, when logistical barriers are reduced [1][2][3].

• Oncology and cardiology programs that added home visits and community‑based data collection observed better alignment of trial demographics with disease epidemiology.

Caveat

• Digital divide and language barriers can blunt benefits if DCT platforms are not designed with equity in mind.

5. Patients with Stable Chronic Diseases in Pragmatic or Long‑Duration Trials

• DCTs are particularly well suited to:

• Long‑term outcomes studies in diabetes, hypertension, heart failure, COPD.

• Adherence, lifestyle, or behavioral interventions where remote monitoring works well.

• Patients avoid repetitive, low‑value visits and can integrate participation into daily life.

Populations Where Benefits Are Less Clear or Conditional

1. Patients with Very Complex, High‑Risk Interventions

• Early‑phase oncology, cell/gene therapies, and interventions requiring frequent intensive monitoring may still need high‑touch, in‑person care.

1. Patients with Severe Cognitive Impairment or Unstable Psychiatric Disease

• DCT participation can be challenging without strong caregiver support and careful risk assessment.

1. Patients with Limited Digital Access or Literacy

• If DCTs rely heavily on smartphones, broadband, or English‑only interfaces, certain older adults, low‑income participants, and some rural or minority communities may not benefit and may even be further excluded.

Actionable Design Principles

To maximize benefits for target populations:

• Hybrid rather than purely remote: Combine local physical touchpoints (community clinics, home health) with telehealth to accommodate varying needs.

• Device and connectivity support: Provide loaner devices, data plans, and tech support.

• Language and cultural tailoring: Multilingual materials, community engagement, and trusted messengers.

• Regulatory alignment: Follow 2026 FDA digital health and DHT guidance to ensure compliant remote data capture [4].